{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:56:26Z","timestamp":1787064986369,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lanepe.2023.100778","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T19:43:06Z","timestamp":1699299786000},"page":"100778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-7511","authenticated-orcid":false,"given":"Fabian","family":"Kerwagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Riemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Abdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-7322","authenticated-orcid":false,"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lanepe.2023.100778_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.lanepe.2023.100778_bib2","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100778_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00392-017-1137-7","article-title":"Epidemiology of heart failure in Germany: a retrospective database study","volume":"106","author":"Stork","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100778_bib4","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ehf2.13407","article-title":"Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification","volume":"8","author":"D\u00f6rr","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"36","key":"10.1016\/j.lanepe.2023.100778_bib5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100778_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.lanepe.2023.100778_bib7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.lanepe.2023.100778_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100778_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.lanepe.2023.100778_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100778_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100778_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100778_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100778_bib14","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ejhf.838","article-title":"The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets","volume":"19","author":"Zaman","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100778_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100778_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ehf2.14197","article-title":"A\u00a0practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Abdin","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"10367","key":"10.1016\/j.lanepe.2023.100778_bib17","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100778_bib18","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ejhf.2378","article-title":"Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100778_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100778_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100778_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2023.100778_bib22","series-title":"European public assessment report","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100778_bib23","series-title":"Summary of product characteristics","year":"2015"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100778_bib24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/pds.5324","article-title":"Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave","volume":"30","author":"Enners","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100778_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1388-9842(03)00050-3","article-title":"Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice","volume":"5","author":"Rutten","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10.1016\/j.lanepe.2023.100778_bib26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/eurheartj\/ehn196","article-title":"Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians","volume":"29","author":"Remme","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lanepe.2023.100778_bib27","series-title":"Sektor\u00fcbergreifende Versorgung bei Herzinsuffizienz","first-page":"109","author":"St\u00f6rk","year":"2021"},{"key":"10.1016\/j.lanepe.2023.100778_bib28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","article-title":"Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US","volume":"8","author":"Pierce","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.lanepe.2023.100778_bib29","series-title":"European public assessment report","year":"2023"},{"key":"10.1016\/j.lanepe.2023.100778_bib30","series-title":"European public assessment report","year":"2023"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100778_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12435","article-title":"The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction","volume":"36","author":"Martens","year":"2018","journal-title":"Cardiovasc Ther"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100778_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006946","article-title":"Reverse cardiac remodeling and outcome after initiation of sacubitril\/valsartan","volume":"13","author":"Januzzi","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"7182","key":"10.1016\/j.lanepe.2023.100778_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","article-title":"Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines","volume":"318","author":"Woolf","year":"1999","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100778_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/PHH.0000000000000673","article-title":"Getting the word out: new approaches for disseminating public health science","volume":"24","author":"Brownson","year":"2018","journal-title":"J\u00a0Public Health Manag Pract"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100778_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ejhf.252","article-title":"Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling","volume":"17","author":"G\u00fcder","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100778_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017765","article-title":"Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review","volume":"8","author":"Shanbhag","year":"2018","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100778_bib37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ejheart.2005.08.005","article-title":"Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis","volume":"7","author":"Roccaforte","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100778_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11897-021-00524-z","article-title":"Guideline-directed medical therapy in females with heart failure with reduced ejection fraction","volume":"18","author":"Agarwal","year":"2021","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100778_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jchf.2022.07.001","article-title":"Age differences in effects of sacubitril\/valsartan on cardiac remodeling, biomarkers, and health status","volume":"10","author":"Murphy","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100778_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030514","article-title":"Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study","volume":"10","author":"Seo","year":"2020","journal-title":"BMJ Open"},{"issue":"16","key":"10.1016\/j.lanepe.2023.100778_bib41","article-title":"Clinical effectiveness of sacubitril\/valsartan among patients hospitalized for heart failure with reduced ejection fraction","volume":"10","author":"Greene","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100778_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100778_bib43","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1111\/jgs.18481","article-title":"Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction","volume":"71","author":"Lee","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100778_bib44","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"38","key":"10.1016\/j.lanepe.2023.100778_bib45","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lanepe.2023.100778_bib46","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100778_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jama.2020.9972","article-title":"Admissions to veterans affairs hospitals for emergency conditions during the COVID-19 pandemic","volume":"324","author":"Baum","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2023.100778_bib48","article-title":"Changes to healthcare utilisation and symptoms for common mental health problems over the first 21 months of the COVID-19 pandemic: parallel analyses of electronic health records and survey data in England","volume":"32","author":"Taxiarchi","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2023.100778_bib49","series-title":"Ver\u00e4nderung der vertrags\u00e4rztlichen Leistungsinanspruchnahme w\u00e4hrend der COVID-Krise\u2013Tabellarischer Trendreport f\u00fcr das 1. Halbjahr 2020 des Zentralinstituts (Zi) f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland","author":"Mangiapane","year":"2020"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100778_bib50","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ejhf.2490","article-title":"Impact of the COVID-19 pandemic on prescription of sacubitril\/valsartan in Italy","volume":"24","author":"Rosano","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100778_bib51","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1093\/eurjpc\/zwab096","article-title":"Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period","volume":"29","author":"Onder","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100778_bib52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cardfail.2021.06.013","article-title":"Prescription filling patterns of evidence-based medical therapies for heart failure during the COVID-19 pandemic in the United States","volume":"27","author":"Vaduganathan","year":"2021","journal-title":"J\u00a0Card Fail"},{"issue":"24","key":"10.1016\/j.lanepe.2023.100778_bib53","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.2020.9184","article-title":"Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States","volume":"323","author":"Vaduganathan","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2023.100778_bib54","article-title":"Impact of COVID-19 on broad-spectrum antibiotic prescribing for common infections in primary care in England: a time-series analyses using OpenSAFELY and effects of predictors including deprivation","volume":"30","author":"Zhong","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100778_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A\u00a0systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.lanepe.2023.100778_bib56","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijcard.2022.06.022","article-title":"The impact of the COVID-19 pandemic on heart failure management: global experience of the OPTIMIZE Heart Failure Care network","volume":"363","author":"Cowie","year":"2022","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100778_bib57","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","article-title":"Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic","volume":"76","author":"Bhatt","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100778_bib58","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ejhf.2044","article-title":"In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network","volume":"22","author":"K\u00f6nig","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100778_bib59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ejhf.2484","article-title":"Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get with the Guidelines-Heart Failure registry","volume":"24","author":"Keshvani","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.lanepe.2023.100778_bib60","series-title":"Imagining the future of pandemics and epidemics: a 2022 perspective","year":"2022"},{"key":"10.1016\/j.lanepe.2023.100778_bib61","series-title":"Ready for the next crisis? Investing in health system resilience","year":"2023"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:56:23Z","timestamp":1763009783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776223001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":61,"alternative-id":["S2666776223001977"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100778","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100778"}}